KRAS and colorectal carcinoma: The objectives of the prospective DECALIB study were to evaluate early detection of colon lesions using cfDNA values, the concordance between tissue and plasma detection of KRAS and BRAF mutations and also the possibility of early detection of CRC lesions using KRAS- or BRAF-mutant ctDNA.